Celconta Group has formulated the "Ten-Hundred-Thousand" five-year development strategy for 2027, that is, to achieve "the cumulative revenue reaching 1 billion, the group valuation reaching 10 billion, and the number of employees reaching 1,000" by 2027, and strive to become a leading enterprise in the field of cell therapy in China.
Celconta Gene Therapy Company (in preparation)
The company uses a know-how-based R&D strategy to find new treatment targets, starting with motor neurone disease and gradually expanding to gene therapy and translational research for other neurodegenerative diseases. It plans to apply for 2-4 patents or orphan drugs, and transform new drug research and development into clinical trials and clinical applications.
